ClinicalTrials.gg
Active, not recruitingNCT06421285Updated Nov 17, 2026

Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer Patients

An interventional study of Aerobic exercise, Strength training, Flexibility exercise in Breast Neoplasms, sponsored by Asan Medical Center. Active, not recruiting at 1 site in South Korea. Open to female participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Asan Medical Center · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 17, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Breast Neoplasms by Asan Medical Center — 2 open to participants now, 3 under way, none of them phase 3. Breast Neoplasms · Asan Medical Center.

Planned enrollment
13th of 16
60 · median 91
Started
2025
with 1 other
No phase
5 of 17
none open now
Registered
14th of 17
by date

Among the 17 studies in Breast Neoplasms by Asan Medical Center, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 with no phase, and was the 14th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 17 studies in Breast Neoplasms by Asan Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Breast Neoplasms by Asan Medical Center, or all of them as a file.
02

Study summary

Research purpose: Lymphedema is a very common complication in breast cancer patients. However, since there is currently no curable treatment, it is important to prevent and reduce the severity of lymphedema. The purpose of this study is to evaluate whether preoperative exercise is effective in preventing lymphedema after surgery. For secondary outcome, the preventive effects of exercise on other upper extremity dysfunctions (eg. pectoralis tightness, Axillary web syndrome, Adhesive capsulitis), which are common in breast cancer patients, were assessed.

Read the detailed description

Study subjects:

  • Patients aged 20 or older who were first diagnosed with breast cancer
  • Patients scheduled to undergo neoadjuvant chemotherapy before surgery Study design: Prospective randomized controlled comparative clinical study
  • Intervention is performed for at least 3 months during the neoadjuvant chemotherapy period before surgery.
  • Treatment group: Individually tailored exercise consisting of aerobic, strength, and flexibility exercises is prescribed, self-exercise compliance monitoring through an application, and diet management education through nutritional counseling.
  • Control group: One session of flexibility exercise training, diet management education through nutritional counseling

Result variable:

  • Primary outcome variable:

    1) Incidence and severity of postoperative lymphedema: bilateral upper limb volume, ICG lymphography

  • Secondary outcome variables:

    1. Clinical information: Demographic, disease and treatment-related data
    2. Physical-related: height/weight/waist circumference measurement, body composition test, physical examination (axillary membrane evaluation)
    3. Upper extremity function (shortening of the pectoralis major muscle, adhesive capsulitis): evaluation of shoulder range of motion, upper extremity muscle strength/grip strength
    4. Quality of life assessment: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast cancer module 23(EORTC QLQ-BR23)

Assessment Schedule:

  • Initial treatment and evaluation: Immediately after breast cancer diagnosis
  • Follow-up evaluation: Immediately after completion of exercise intervention (preoperatively), and at 1, 3, and 6 months postoperatively.

Number of study subjects:

  • This study will be conducted as a preliminary study for future research, and will be conducted on a total of 60 patients (30 in the experimental group and 30 in the control group) with an allocation ratio between groups of 1:1.
03

Conditions studied

  • Breast Neoplasms

Keywords

  • Preoperative Exercise
  • Lymphedema
  • Breast Cancer
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 20 or older and younger than 80 who were first diagnosed with breast cancer
  • Patients scheduled for surgery and starting chemotherapy before surgery

Exclusion criteria

Exclusion Criteria:

  • Patients with medical to exercise intervention or pain or musculoskeletal conditions that may limit active exercise intervention
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Individually tailored exercise consisting of aerobic, strength, and flexibility exercises is prescribed, self-exercise compliance monitoring through an application, and diet management education through nutritional counseling.

    Behavioral: Aerobic exercise, Strength training, Flexibility exercise

  • No intervention
    Control group

    One session of flexibility exercise education, diet management education through nutritional counseling

Interventions

  • BehavioralAerobic exercise, Strength training, Flexibility exercise

    Aerobic exercise: 30-40 minutes/time, 3-5 times a week, intensity of 4-6 points on the Rating of Perceived Exertion(RPE) 10-point scale(A simple conversation is possible during exercise, but the intensity is such that you feel out of breath) Strength training: 2-3 times a week, 3 sets of 10 repetitions per movement * Upper extremities: Biceps brachii, triceps brachii, deltoid, pectoralis muscle exercise * Lower extremities: gluteus maximus, hamstrings, quadriceps exercise Flexibility exercise: Stretching and mobility exercises reflecting post-surgery rehabilitation

06

What researchers measure

Primary outcomes

  1. Bilateral upper limb volume

    Using a tape measure, measure the circumference from the wrist to the armpit every 4cm, then apply the ΣCircumference2/π formula to calculate the volume of the upper limb.

    Time frame: Immediately, Preoperatively, 1 month, 3 months, 6 months.

  2. ICG lymphography

    Indocyanine green (ICG) contrast agent is injected subcutaneously in the distal area, and lymph fluid flowing to the proximal area through collateral lymphatic vessels is checked with an infrared camera.

    Time frame: Immediately, 1 month, 6 months.

Secondary outcomes

  1. Body composition

    After attaching electrodes to both hands and feet using the Inbody S10 equipment, quantitatively evaluate body composition by measuring human body impedance using multiple frequencies.

    Time frame: Immediately, 6 months.

  2. Shoulder range of motion

    Measurements are made according to a standardized protocol using a goniometer.

    Time frame: Immediately, Preoperatively, 1 month, 3 months, 6 months.

  3. Upper limb strength, grip strength

    Using a digital hand held dynamometer, the strength of elbow flexion and extension, shoulder abduction, and flexor extensor muscles was measured. Measure grip strength using a digital hand held dynamometer

    Time frame: Immediately, 6 months

  4. EORTC QLQ-C30

    Evaluate the patient's quality of life through the corresponding questionnaire

    Time frame: Immediately, 6 months

  5. EORTC QLQ-BR23

    Evaluate the patient's quality of life through the corresponding questionnaire

    Time frame: Immediately, 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Oct 2025 → Feb 2027 and completion Dec 2025 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 20, 2024
StartActual
Jan 10, 2025
Primary completionEst.
Feb 1, 2027was Oct 2025
CompletionEst.
Mar 31, 2027was Dec 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Primary completion
Oct 30, 2025→Feb 1, 2027
Nov 17, 2026
Study completion
Dec 31, 2025→Mar 31, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 30, 2025→Feb 1, 2027
    Study completion Dec 31, 2025→Mar 31, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06421285
Responsible party
Jae Yong Jeon, MD (Professor, Asan Medical Center) — Principal investigator
First posted
May 20, 2024
Start date
Jan 10, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Jaeyong Jeon
principal investigator · Asan Medical Center
Heejeong Kim
study chair · Asan Medical Center
Seungwoo Cha
study chair · Asan Medical Center
Hwayeong Cheon
study chair · Asan Medical Center
Junghwa Do
study chair · Asan Medical Center
Woojin Jeong
study chair · Asan Medical Center
Ahnhee Kim
study chair · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion